Drug Profile
Research programme: HIV-1 integrase inhibitors - Pfizer
Alternative Names: PF-00558475Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Pfizer
- Class Aza compounds; Indoles
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-1-infections in USA
- 19 Apr 2008 Preclinical development is ongoing
- 21 Jun 2000 Warner-Lambert has merged with Pfizer